News & Industry Updates | Recombinant Oryza Sativa Protein,Rice-Derived Recombinant Proteins

NMPA Approval Milestone: What Olbumin®’s Drug License (S20250039) Means for Global Biopharma Suppliers

cGMP-Grade Recombinant Albumin: What DMF 29648 Means for Your Biopharma Filing

Stabilizing Vaccines and Viral Vectors: The Role of Plant-Made Recombinant Albumin

Why Rice-Derived Recombinant Human Albumin Is Becoming the Preferred Choice for Xeno-Free Cell Culture

Healthgen Obtains CMMM Level 3 Certification

ISSCR 2026-Healthgen Biotech showcases rice-derived rHSA

Healthgen Biotech continues to deepen its footprint in stem cell and regenerative medicine, actively advancing global standards for serum-free culture systems, CGT process quality control, and clinical compliance.

Healthgen Biotech to attend KOREA PHARM & BIO 2026

31th March to 3rd April. Gyeonggi-do,Seoul

Healthgen Announces Listing on October 28, 2025

(Stock Name: Healthgen Biotech; Stock Code: 688765) Shanghai Stock Exchange, the first listed company specializing in recombinant human albumin.

Gut commentary highlighting the significant clinical implications of Olbumin®

The authoritative international hepatology journal Gut published a commentary highlighting the significant clinical implications of Recombinant Human Albumin Injection (Oryza Sativa)in albumin therapy

Olbumin® receives approval to initiate Phase III Clinical Trials in US

Recombinant Human Albumin Injection (Oryza Sativa) receives approval to initiate Phase III Clinical Trials in the United States